Tideglusib for Congenital and Childhood-Onset Myotonic Dystrophy Type 1
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Pediatric Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)
Pediatr. Neurol. 2020 Nov 01;112(xx)84-93, J Horrigan, TB Gomes, M Snape, N Nikolenko, A McMorn, S Evans, A Yaroshinsky, O Della Pasqua, S Oosterholt, H LochmüllerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.